Work

One-bag protocol for cancer drug hypersensitivity

Year: 2025

Type: article

Study designs: Systematic Review, Meta-Analysis

Abstract: BACKGROUND: Hypersensitivity reactions (HSRs) to essential chemotherapy create treatment barriers in cancer care globally. Conventional 3-bag protocols (3BPs) for rapid drug desensitization (RDD) present operational challenges that may inadvertently exacerbate health care disparities. OBJECTIVE: To systematically evaluate the safety, completion rates, and procedural duration of 1BP for chemotherapy and monoclonal antibody HSRs and to compare these outcomes with those of conventional 3BP. METHODS: In this meta-analysis, we searched MEDLINE, Embase, Web of Science, and CENTRAL. We included studies describing 1BP for HSRs to chemotherapy and monoclonal antibodies. Four reviewers independently screened the studies and extracted the data. The primary outcome was the pooled completion rate of 1BP. Secondary outcomes compared safety, completion rates, and protocol duration between the 1BP and 3BP. RESULTS: Our analysis of 16 studies included 975 patients undergoing 4473 RDD procedures. The pooled completion rate for 1BP was 99.7% (95% CI: 99.35%-99.9%; prediction interval: 98%-100%), remaining consistent across drug classes. Although breakthrough reaction occurred in 12% of RDDs, they were predominantly mild to moderate, with only 0.4% being severe. In studies comparing protocols, there was no significant difference in completion rates (risk difference: 0.00; P = .966). CONCLUSION: The 1BP RDD protocols demonstrate consistent safety and completion rates. Our findings suggest that patient safety relies on the precise control of exposure kinetics rather than multiple dilution steps. By reducing procedural complexity and duration, 1BP provides a robust strategy to streamline workflows, optimize resource allocation, and enhance patient access to cancer therapies across diverse health care settings. INTERNATIONAL PROSPECTIVE REGISTER OF SYSTEMATIC REVIEWS (PROSPERO) REGISTRATION: CRD42024586580.

Source: Annals of Allergy Asthma & Immunology

DOI: 10.1016/j.anai.2025.06.034